|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Product revenue, net | |||||
| Product revenue, net | |||||
| Milestone revenue | |||||
| Total product revenue, net | |||||
| Operating expenses | |||||
| Cost of sales | |||||
| Research and development | |||||
| Total selling, general and administrative expenses | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Gain on sale of contingent payments | |||||
| Milestone payment from gain on sale of oncology business | |||||
| Royalty income from gain on sale of oncology business | |||||
| Interest income, net | |||||
| Other income, net | |||||
| Net (loss) income before taxes | |||||
| Net income from discontinued operations, net of tax | |||||
| Income tax (benefit) expense | |||||
| Net (loss) income | |||||
| Net loss from continuing operations per share - basic (in usd per share) | |||||
| Net income from discontinued operations per share - basic (in usd per share) | |||||
| Net income (loss) per share - basic (in usd per share) | |||||
| Net income (loss) per share - diluted (in usd share) | |||||
| Weighted-average number of common shares used in computing net income (loss) per share – basic (in shares) | |||||
| Weighted-average number of common shares used in computing net income (loss) per share – diluted (in shares) |
Loading...
